Clinical Trials Directory

Trials / Completed

CompletedNCT03520543

[11C]Yohimbine PET Study of alpha2-AR

Positron Emission Tomography Study of alpha2-adrenergic Receptors With [11C]Yohimbine

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
Male
Age
20 Years – 35 Years
Healthy volunteers
Accepted

Summary

The main purpose of this study is to model tissue specific kinetics of \[11C\]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of \[11C\]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).

Conditions

Interventions

TypeNameDescription
DRUG[11C]YohimbineEach subject will receive an intravenous (IV) bolus injection of \[11C\]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of \[11C\]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of \[11C\]Yohimbine.
DRUG[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following \[11C\]Yohimbine PET scan (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after \[11C\]Yohimbine PET scan of part A. Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of \[11C\]Yohimbine (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of \[11C\]Yohimbine obtained at baseline (part A).

Timeline

Start date
2018-05-21
Primary completion
2018-07-21
Completion
2019-01-21
First posted
2018-05-09
Last updated
2025-09-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03520543. Inclusion in this directory is not an endorsement.